Why Omeros Stock Is Sliding Today Even as Biotech Shares Climb
Omeros shares fell 3.9% to $11.20 in late-morning trading Wednesday, underperforming biotech sector ETFs, which gained. The drop followed the company’s first U.S. launch of YARTEMLEA, which posted $9.9 million in Q1 sales after FDA approval in December. Investors are watching for upcoming reimbursement milestones and a pending European review.
